VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA ...
Lawyersclubindia5d
Trade Dress vs Trademark: The Legal and Branding Power of Packaging in the Food Industry
IntroductionThe evolution of packaging from ancient times to modernity reflects not only technological advances but also the ...
Eli Lilly (LLY): “I Still Like It” – Cramer Sees Opportunity on the Dip
We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim ...
Port City Daily4d
Small Bites: New Indian and pho restaurants, plus a coffee truck
Lots of movement happens around the Port City when it comes to restaurants, food trucks, bars and bottle shops, not to ...
Cumberland announces NMPA approval of Vibativ injection in China
Pharmaceuticals announced the NMPA, National Medical Products Administration, approval of Cumberland’s Vibativ injection in ...
Mint6d
Three global PE firms vie to buy Hyderabad’s Gland Pharma from its Chinese owner
Fosun has been looking to exit its investment in Gland Pharma since 2020, when geopolitical tensions between India and China escalated. In June 2024, the Chinese pharma company sold around 6% of i ...
ROSEN, A LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), of ...
U.S. investors, Big Pharma race to find new medicines in China
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Mint6d
Five Indian stocks that could benefit from Trump’s tariffs on China
With a 10% tariff on imports, Chinese pharma products will become costlier for the US intermediaries, forcing them to look for alternatives. Also read: Hexaware's IPO: A risky gamble in uncertain ...
Independent Medical Alliance Publishes Inaugural Issue of the Journal of Independent Medicine
Today, the Independent Medical Alliance (IMA), formerly FLCCC, proudly announces the Journal of Independent Medicine, a groundbreaking peer-reviewed publication dedicated to restoring integrity, ...
Nature5d
Approvals by the China NMPA in 2024
Both PD-1 inhibitors independently developed by Chinese pharma companies had been approved by the FDA. In addition, BeiGene’s zanubrutinib (Brukinsa) received conditional approval from the NMPA ...
News Medical6d
Selkirk Pharma introduces ClinFAST™ to expedite fill/finish for clinical trials
Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...